Multiple Sclerosis Foundation

Recent papers from Multiple Sclerosis Foundation

1. Cell-specific proteome profiling reveals altered peripheral immune cell communication in early multiple sclerosisCommunications Medicine · 2026
2. A group resilience training program for people with multiple sclerosis: A cluster-randomized controlled trial (multi-READY for MS)Multiple Sclerosis Journal · 2026
3. Clinicians’ experiences and perspectives on robot-assisted lower limb and gait neurorehabilitation in Western AustraliaDisability and Rehabilitation · 2026
4. Diagnostic value of the kappa free light chain index in multiple sclerosis under the 2024 CSF positivity criterion: a multicentre study in oligoclonal band-negative patientsFrontiers in Immunology · 2026
5. A community-validated tool for clinical outcome calculation in multiple sclerosis: Consensus development and scenario-specific recommendationsMultiple Sclerosis Journal · 2026
6. Predictors of subsequent relapse-independent progression after high-efficacy therapy in relapsing multiple sclerosisFrontiers in Immunology · 2026
7. Anti-CD6 monoclonal antibody UMCD6 induces CD6 internalization, remodels costimulatory receptor availability, and modulates CD4+ T-cell activationFrontiers in Immunology · 2026
8. Anti‐ CD20 Discontinuation Versus Continuation in People Aged Over 50 With Non‐Active Multiple SclerosisAnnals of Clinical and Translational Neurology · 2026
9. Real‐World Data for Safety Studies: Challenges and Opportunities From the Italian Multiple Sclerosis and Related Disorders RegisterPharmacoepidemiology and Drug Safety · 2026
10. Safety and Effectiveness of Dimethyl Fumarate in Japanese Patients With Multiple Sclerosis: Subgroup Analysis of Older Patients and Patients Switching From Fingolimod or Natalizumab Using 2‐Year Post‐Marketing Surveillance DataClinical and Experimental Neuroimmunology · 2026
11. From cellular diversity to coordinating nervous system function: the next frontier in non-neuronal cell biologyFrontiers in Cellular Neuroscience · 2026
12. Treatment escalation after clinically silent MRI lesions in relapsing-remitting multiple sclerosisBrain · 2026
13. The impact of multiple sclerosis on social determinants of health: Results from the SocialMS studyMultiple Sclerosis and Related Disorders · 2026
14. Temporal context shapes multicue integration in auditory time-to-contact judgmentsScientific Reports · 2026
15. Optimizing Infusion Center Efficiency in Multiple Sclerosis: A Nursing Multicenter Survey on Organizational Impact of UblituximabHealthcare · 2026
16. A Comparative Clinical Effectiveness Trial of Rituximab Versus Ravulizumab, Inebilizumab, Satralizumab, and Eculizumab to Prevent Relapses in Neuromyelitis Optica Spectrum Disorder (NMOSD) (P3-1.001)Neurology · 2026
17. Linking Real-world Mobility to Molecular Markers of Neuroaxonal Damage in People With Progressive Multiple Sclerosis (P4-18.002)Neurology · 2026
18. Conformational PLP-1 Antibodies as a Prognostic Biomarker in MOGAD (S6.010)Neurology · 2026
19. A Comparative Effectiveness Analysis of Fumarates versus Cladribine in People With MS Transitioning From Anti-CD20 Therapies (P1-20.008)Neurology · 2026
20. Safety of Non-MS Biologics in Patients with Multiple Sclerosis: A Multi-center Retrospective Study of MS Patients with Co-morbid Autoimmune Conditions (S40.007)Neurology · 2026